Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$2.90 +3.6%	$2.64	$1.83 ▼ $7.63	$2.56B	0.33	5.50 million shs	12.46 million shs
IMVT Immunovant	$15.00 +2.0%	$15.76	$12.72 ▼ $34.47	$2.55B	0.75	1.22 million shs	830,358 shs
MLTX MoonLake Immunotherapeutics	$40.28 +2.8%	$38.45	$31.42 ▼ $58.26	$2.51B	1.31	353,800 shs	244,937 shs
VIR Vir Biotechnology	$4.73 +1.9%	$5.87	$4.32 ▼ $14.45	$653.87M	1.36	1.37 million shs	1.51 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	+3.57%	+15.54%	+17.41%	-25.64%	-58.81%
IMVT Immunovant	+2.04%	+6.99%	-0.99%	-27.95%	-51.41%
MLTX MoonLake Immunotherapeutics	+2.76%	+4.51%	+5.09%	-3.87%	+4.19%
VIR Vir Biotechnology	+1.94%	+0.64%	-14.00%	-51.98%	-51.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IBRX ImmunityBio	1.9084 of 5 stars	3.6	1.0	2.0	1.7	0.6
IMVT Immunovant	2.7632 of 5 stars	4.5	1.0	3.7	1.7	0.0
MLTX MoonLake Immunotherapeutics	3.3414 of 5 stars	4.5	2.0	3.9	2.5	0.0
VIR Vir Biotechnology	3.1252 of 5 stars	3.4	1.0	4.0	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBRX ImmunityBio	3.20	Buy	$12.25	322.41% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	155.56% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$78.71	95.42% Upside
VIR Vir Biotechnology	2.86	Moderate Buy	$32.86	594.65% Upside

Current Analyst Ratings Breakdown

Latest VIR, MLTX, IMVT, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/19/2025	MLTX MoonLake Immunotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$61.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$78.00 ➝ $80.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
5/12/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/12/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00
5/5/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/30/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/28/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/23/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBRX ImmunityBio	$31.22M	81.98	N/A	N/A	($0.88) per share	-3.30
IMVT Immunovant	N/A	N/A	N/A	N/A	$2.08 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$8.15 per share	N/A
VIR Vir Biotechnology	$14.30M	45.72	N/A	N/A	$11.82 per share	0.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBRX ImmunityBio	-$583.20M	-$0.58	N/A	N/A	N/A	-8,016.83%	N/A	-110.02%	N/A
IMVT Immunovant	-$259.34M	-$2.62	N/A	N/A	N/A	N/A	-77.94%	-69.82%	6/4/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$36.01M	-$2.30	N/A	N/A	N/A	N/A	-15.54%	-15.09%	8/6/2025 (Estimated)
VIR Vir Biotechnology	-$615.06M	-$4.22	N/A	N/A	N/A	-678.40%	-36.71%	-31.00%	7/30/2025 (Estimated)

Latest VIR, MLTX, IMVT, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/4/2025	Q4 2025	IMVT Immunovant	-$0.72	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
3/3/2025	Q4 2024	IBRX ImmunityBio	-$0.26	-$0.15	+$0.11	-$0.09	$8.74 million	$7.55 million
2/26/2025	Q4 2024	MLTX MoonLake Immunotherapeutics	-$0.63	-$0.72	-$0.09	-$0.72	N/A	N/A
2/26/2025	Q4 2024	VIR Vir Biotechnology	-$0.85	-$0.76	+$0.09	-$0.76	$8.14 million	$12.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBRX ImmunityBio	N/A	2.68	2.64
IMVT Immunovant	N/A	6.04	6.04
MLTX MoonLake Immunotherapeutics	N/A	25.51	25.51
VIR Vir Biotechnology	N/A	8.94	8.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBRX ImmunityBio	8.58%
IMVT Immunovant	47.08%
MLTX MoonLake Immunotherapeutics	93.85%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
IBRX ImmunityBio	76.79%
IMVT Immunovant	5.90%
MLTX MoonLake Immunotherapeutics	12.02%
VIR Vir Biotechnology	15.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBRX ImmunityBio	590	882.62 million	115.67 million	Optionable
IMVT Immunovant	120	169.86 million	159.84 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.22 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.24 million	Optionable

VIR, MLTX, IMVT, and IBRX Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by D. E. Shaw & Co. Inc.

May 21 at 4:03 AM | marketbeat.com

Stonepine Capital Management LLC Takes Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 20 at 7:02 AM | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages

May 20 at 6:12 AM | marketbeat.com

Sphera Funds Management LTD. Boosts Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 18 at 6:55 AM | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Algert Global LLC

May 16, 2025 | marketbeat.com

Orbimed Advisors LLC Reduces Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 15, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Hudson Bay Capital Management LP

May 15, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week Low After Analyst Downgrade

May 15, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at Needham & Company LLC

May 14, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Price Target Cut to $14.00 by Analysts at Needham & Company LLC

May 13, 2025 | americanbankingnews.com

Vir’s hepatitis B combo falls short in Phase II trial

May 12, 2025 | msn.com

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025 | businesswire.com

Bridgeway Capital Management LLC Sells 66,538 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

May 12, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Dimensional Fund Advisors LP

May 11, 2025 | marketbeat.com

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint

May 10, 2025 | finance.yahoo.com

DAFNA Capital Management LLC Invests $734,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 10, 2025 | marketbeat.com

Why Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%

May 10, 2025 | aaii.com

Q1 2025 Vir Biotechnology Inc Earnings Call

May 10, 2025 | finance.yahoo.com

Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2

May 10, 2025 | fiercebiotech.com

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 9, 2025 | businesswire.com

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress

May 8, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
NVIDIA Stock Surges on Bullish News: How High Could It Climb?
By Thomas Hughes | May 13, 2025
View NVIDIA Stock Surges on Bullish News: How High Could It Climb?
Medtronic: A Dividend Aristocrat With Stability and Innovation
By Jeffrey Neal Johnson | April 22, 2025
View Medtronic: A Dividend Aristocrat With Stability and Innovation

VIR, MLTX, IMVT, and IBRX Company Descriptions

ImmunityBio NASDAQ:IBRX

$2.90 +0.10 (+3.57%)

As of 05/20/2025 04:00 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Immunovant NASDAQ:IMVT

$15.00 +0.30 (+2.04%)

As of 05/20/2025 04:00 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

MoonLake Immunotherapeutics NASDAQ:MLTX

$40.28 +1.08 (+2.76%)

As of 05/20/2025 04:00 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Vir Biotechnology NASDAQ:VIR

$4.73 +0.09 (+1.94%)

As of 05/20/2025 04:00 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time